Valvular & structural heart diseaseCohort study

Long-Term Impact of Mild Paravalvular Regurgitation After Transcatheter Aortic Valve Replacement

JACC Cardiovasc IntervPublished

  • Registry-based cohort study

Authors' conclusion

Mild PVR after TAVR is associated with a significantly increased risk for BVF and all-cause mortality

Study context

Population
Patients after transcatheter aortic valve replacement (TAVR) with no, trace or mild paravalvular regurgitation (PVR) at discharge (OCEAN-TAVI registry)median follow-up 4.7 years
Participants
5,068 patients
Exposure
Mild PVR vs no or trace PVR after TAVR
  • Mild PVRn = 1,601
Outcome
All-cause mortality and bioprosthetic valve failure (BVF, VARC-3 criteria)
Follow-up
Up to 9 years

Main finding

As reported in the abstract

All-cause mortality and BVF

Mild PVR

75.9% (95% CI: 71.3%-80.2%)

All-cause mortality · bioprosthetic valve failure (BVF) 20.7% (95% CI: 12.8%-32.5%)

No or trace PVR

72.2% (95% CI: 68.1%-76.3%)

All-cause mortality · BVF 17.3% (95% CI: 11.0%-26.6%)

Mild PVR vs No or trace PVREstimate (95% CI)P value
BVF, Fine-Gray; cumulative incidence P = 0.029
sHR 1.48(1.07–2.04)
P = 0.018
all-cause mortality, Cox; log-rank P = 0.014
HR 1.11(1.02–1.21)
P = 0.014

Observational data: associations, not effects.

Further findings

OutcomeEstimateP value
BVF by subgroup — Mild PVR vs No or trace PVR · balloon-expandable valvessHR 1.46 (95% CI 1.02–2.08)P = 0.038
BVF by subgroup — Mild PVR vs No or trace PVR · nontransfemoral TAVRsHR 5.58 (95% CI 1.57–19.9)P = 0.0086
BVF by subgroup — Mild PVR vs No or trace PVR · eGFR < 30 mL/min/1.73 m²sHR 3.86 (95% CI 1.30–11.5)P = 0.015
Progression to moderate or greater PVRHR 3.74 (95% CI 2.84–4.92)P < 0.001

Original publication

Long-Term Impact of Mild Paravalvular Regurgitation After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. Published 14 November 2025. doi:10.1016/j.jcin.2025.09.004

Summarised from the published abstract; every number is checked against it